Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
84 hedge funds and large institutions have $44.4M invested in Paratek Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 31 reducing their positions, and 28 closing their positions.
75% more call options, than puts
Call options by funds: $173K | Put options by funds: $99K
16% less funds holding
Funds holding: 100 → 84 (-16)
32% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 31
46% less capital invested
Capital invested by funds: $82.1M → $44.4M (-$37.7M)
50% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 28
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$755K |
| 2 |
GAI
General American Investors
New York
|
+$664K |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$540K |
| 4 |
E
Ergoteles
New York
|
+$498K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$406K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.52M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$2.26M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.59M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.33M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$807K |
PRTK Hedge Fund Activity: Q2 2022 in Review
84 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2022, worth a combined $44.4M — down 46% from $82.1M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of PRTK and 14 opened new positions — a net loss of 14 holders — while 31 trimmed existing stakes and 21 added.
The largest buyer was Millennium Management, adding an estimated $755K. The largest seller was BlackRock, cutting an estimated $4.52M.
- 84 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2022, down from 100 in Q1 2022.
- Funds reported $44.4M of Paratek Pharmaceuticals, Inc. stock for Q2 2022, down 46% quarter-over-quarter.
- 14 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2022 and 28 closed out, a net change of -14 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2022 was Millennium Management, an estimated $755K added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q2 2022 was BlackRock, an estimated $4.52M sold.
Based on aggregated 13F filings for Q2 2022.